Rhumbline Advisers Increases Stock Holdings in Genmab A/S Sponsored ADR $GMAB

Rhumbline Advisers boosted its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 3.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 16,956 shares of the company’s stock after purchasing an additional 532 shares during the period. Rhumbline Advisers’ holdings in Genmab A/S were worth $332,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in GMAB. Squarepoint Ops LLC lifted its position in shares of Genmab A/S by 1,235.0% during the 4th quarter. Squarepoint Ops LLC now owns 117,507 shares of the company’s stock valued at $2,452,000 after buying an additional 108,705 shares in the last quarter. Vise Technologies Inc. increased its stake in Genmab A/S by 41.7% in the 4th quarter. Vise Technologies Inc. now owns 12,892 shares of the company’s stock worth $269,000 after acquiring an additional 3,794 shares during the last quarter. Mackenzie Financial Corp bought a new stake in Genmab A/S in the 4th quarter worth approximately $689,000. Marotta Asset Management increased its position in shares of Genmab A/S by 5.8% during the 1st quarter. Marotta Asset Management now owns 13,532 shares of the company’s stock valued at $265,000 after purchasing an additional 739 shares during the last quarter. Finally, Versant Capital Management Inc increased its position in shares of Genmab A/S by 1,108.3% during the 1st quarter. Versant Capital Management Inc now owns 8,724 shares of the company’s stock valued at $171,000 after purchasing an additional 8,002 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Trading Up 2.5%

Shares of GMAB opened at $29.45 on Thursday. Genmab A/S Sponsored ADR has a 12 month low of $17.24 and a 12 month high of $29.52. The stock’s 50 day moving average is $24.68 and its two-hundred day moving average is $21.93. The firm has a market cap of $18.89 billion, a P/E ratio of 14.80, a PEG ratio of 1.68 and a beta of 0.93.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.39 by $0.15. The company had revenue of $925.00 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. Equities research analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on GMAB. HC Wainwright boosted their target price on Genmab A/S from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Friday, August 15th. Guggenheim raised Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target on the stock in a research report on Tuesday. Wall Street Zen upgraded Genmab A/S from a “hold” rating to a “buy” rating in a research note on Monday, July 28th. Truist Financial increased their price target on Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 8th. Finally, Zacks Research cut Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.